安杰思(688581) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was RMB 59,720.71 million, a decrease of 6.19% compared to the previous year[2] - Net profit attributable to shareholders was RMB 22,281.69 million, down 24.06% year-on-year[2] - Net profit excluding non-recurring gains and losses was RMB 19,141.86 million, a decline of 29.81% from the previous year[2] - Basic earnings per share decreased to RMB 2.77, down 23.90% compared to RMB 3.64 in the previous year[2] Assets and Equity - Total assets increased to RMB 267,401.41 million, reflecting a growth of 4.87% from the beginning of the period[2] - Shareholders' equity attributable to the parent company rose to RMB 251,585.13 million, an increase of 4.95%[2] Market Challenges and Strategies - The company faced challenges due to intensified competition in the minimally invasive endoscopic treatment sector and external factors like centralized procurement policies[7] - The company continued to invest in R&D and automation to enhance product competitiveness and maintain stable gross margins[7] - The company is focusing on global expansion, particularly in local operations in the Netherlands and the construction of a production base in Thailand[7] - High investments in R&D, production line updates, and market operations have impacted current profits but are expected to support future growth[7]